Novel actions of progesterone: What we know today and what will be the scenario in the future?

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 8, 2012, Pages 1040-1062

  Kaore, Shilpa N ^a   Langade, Deepak Kumar ^b   Yadav, Vijay Kumar ^b   Sharma, Parag ^b   Thawani, Vijay R ^c   Sharma, Raj ^d  

^a People's College of Medical Sciences and Research Center   (India)

^b Peoples College of Medical Sciences and RC   (India)

^c VCSG GMSRI ^*  (India)

^d Government Medical College   (India)

Author keywords

Alzheimer's; BPH; Neurosteroid; Progesterone; Traumatic brain injury

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 6 METHYLENEPROGESTERONE; ALLYLESTRENOL; ANDROSTANOLONE; BRASSINOLIDE; CYPROTERONE ACETATE; EPIRUBICIN; EPRISTERIDE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRAMUSTINE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; HYDROXYPROGESTERONE ACETATE; HYDROXYPROGESTERONE CAPROATE; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PREDNISOLONE; PREMPAK; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BREAST CANCER; CANCER INHIBITION; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CRUSH TRAUMA; DIABETIC NEUROPATHY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENDOMETRIUM HYPERPLASIA; HORMONAL CONTRACEPTION; HORMONE INHIBITION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; KIDNEY CARCINOMA; MELANOMA; NEUROPROTECTION; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PARENTAL BEHAVIOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PREECLAMPSIA; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TOBACCO DEPENDENCE; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN DISEASES; BRAIN INJURIES; CONTRACEPTIVE AGENTS, MALE; FEMALE; HUMANS; MALE; MEGESTROL ACETATE; NORETHINDRONE; OSTEOPOROSIS; PROGESTERONE; PROGESTINS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84863724524     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01464.x     Document Type: Review

References (278)

1. Drugsupdate.com (Internet). India: progesterone information from drugsupdate. 2010 Available at: (accessed 16 September 2010).
2. Katzung BG,. The Gonadal Hormones and Inhibitors; Basic & Clinical Pharmacology, 10th edn. Boston, MA: McGraw Hill Publishers, 2007: 661.
3. Feeser VR, Loria RM,. Modulation of traumatic brain injury using progesterone and the role of glial cells on its neuroprotective actions. J Neuroimmunol 2011; 237: 4-12.
4. Stein DG, Wright DW,. Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs 2010; 19: 847-857.
5. Hu Z, et al,. Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration. Curr Med Chem 2009; 16: 1418-1425.
6. Teitelbaum P,. Functional recovery after lesions of the nervous system. V. Neural plasticity and behavioral recovery in the central nervous system. The use of recovery of function to analyze the organization of motivated behavior in the nervous system. Neurosci Res Program Bull 1974; 12: 255-260.
7. Milner B, et al,. Developmental processes in neural plasticity. Neurosci Res Program Bull 1974; 12: 212-213.
8. Stein DG,. Is progesterone a worthy candidate as a novel therapy for traumatic brain injury? Dialogues Clin Neurosci 2011; 13: 352-359.
9. Jiang N, et al,. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res 1996; 735: 101-107. (Pubitemid 26336624)
10. Sayeed I, Stein DG,. Progesterone as a neuroprotective factor in traumatic and ischemic braininjury. Prog Brain Res 2009; 175: 219-237.
11. Baulieu EE, et al,. Progesterone as a neurosteroid: actions within the nervous system. Cell Mol Neurobiol 1996; 16: 143-154. (Pubitemid 26158374)
12. Blackmore PF, et al,. Cell surface-binding sites for progesterone mediated calcium-uptake in human sperm. J Biol Chem 1991; 266: 18655-18659. (Pubitemid 21908134)
13. Filardo EJ Jr,. et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-1660.
14. Zhu Y, et al,. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 2003; 100: 2231-2236. (Pubitemid 36297482)
15. Skildum A, et al,. Progesterone receptors induce cell cycle progression via mitogenactivated protein kinases. Mol Endocrinol 2005; 19: 327-339. (Pubitemid 40223458)
16. Boonyaratnakonkit V, et al,. Progesterone receptor contains a praline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinase. Mol Cell 2001; 8: 269-280.
17. Jodhka PK, et al,. The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression. Endocrinology 2009; 150: 3162-3168.
18. Singh M,. Progestins and neuroprotection: are all progestins created equal? Minerva Endocrinol 2007; 32: 95-102.
19. Nilsen J, Brinton RD,. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 2003; 100: 10506-10511. (Pubitemid 37071908)
20. Rosano GM, et al,. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000; 36: 2154-2159.
21. Nilsen J, Brinton RD,. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002; 143: 205-212. (Pubitemid 34056421)
22. Prior JC, et al,. Cyclicmedroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 1994; 96: 521-530. (Pubitemid 24184437)
23. Foy MR,. Ovarian hormones, aging and stress on hippocampal synaptic plasticity. Neurobiol Learn Mem 2011; 95: 134-144.
24. Singh M,. Mechanisms of progesterone-induced neuroprotection. Ann NY Acad Sci 2005; 1052: 145-151. (Pubitemid 41338964)
25. Singh M,. Progesterone-induced neuroprotection. Endocrine 2006; 29 271-274. (Pubitemid 44097368)
26. Melcangi RC, et al,. Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 2008; 65: 777-797.
27. Reddy DS,. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 2003; 15: 197-234. (Pubitemid 38931485)
28. Chisari M, et al,. The sticky issue of neurosteroids and GABA(A) receptors. Trends Neurosci 2010; 33: 299-306.
29. Herd MB, et al,. Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther 2007; 116: 20-34. (Pubitemid 47391030)
30. Belelli D, Lambert JJ,. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005; 6: 565-575. (Pubitemid 40942823)
31. Melcangi RC, et al,. Peripheral nerves: a target for the action of neuroactive steroids. Brain Res Brain Res Rev 2005; 48: 328-338. (Pubitemid 40585763)
32. Pesaresi M, et al,. Dihydroprogesterone increases the gene expression of myelin basic protein in spinal cord of diabetic rats. J Mol Neurosci 2010; 42: 135-139.
33. Girish C, et al,. Asoprisnil: a selective progesterone receptor modulator. Indian J Pharmacol 2005; 37: 266-267. (Pubitemid 41168916)
34. Chwalisz K, et al,. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 2004; 22: 113-119. (Pubitemid 38691954)
35. Chwalisz K, et al,. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Rev 2005; 26: 423-438. (Pubitemid 40686652)
36. Yoshida S, et al,. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260-273.
37. Maruo T, et al,. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007; 75 (Suppl.): S99-103. (Pubitemid 46770714)
38. Glasier AF, et al,. Ulipristal acetate versus levonorgesterel for emergency contraception: a randomised non-inferiority trial and metaanalysis. Lancet 2010; 375: 555-562.
39. DeManno D, et al,. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003; 68: 1019-1032.
40. Maruo T, et al,. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception 2010; 82: 435-441.
41. Xu Q, et al,. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181-191. (Pubitemid 351404891)
42. Chen W, et al,. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006; 91: 1296-1304.
43. Sasaki H, et al,. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2007; 92: 616-623.
44. Kareva EN, et al,. Gestagens and the brain. Vestn Ross Akad Med Nauk 2010; 6: 40-49.
45. Labombarda F, et al,. Progesterone and the spinal cord: good friends in bad times. Neuroimmunomodulation 2010; 17: 146-149.
46. Dableh LJ, Henry JL,. Progesterone prevents development of neuropathic pain in a rat model: timing and duration of treatment are critical. J Pain Res 2011; 5: 91-101.
47. Gonzalez SL, et al,. Progesterone neuroprotection in spinal cord traumainvolves up-regulation of brain-derived neurotrophic factor in motoneurons. J Steroid Biochem Mol Biol 2005; 94: 143-149. (Pubitemid 40614527)
48. Schacter L, et al,. Megestrol acetate: clinical experience. Cancer Treat Rev 1989; 16: 49-63. (Pubitemid 19171295)
49. Gann PH, et al,. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118-1126. (Pubitemid 26274606)
50. Petrow V,. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications. Prostate 1986; 9: 343-361. (Pubitemid 17219906)
51. Schneider JS, et al,. Effects of progesterone on male-mediated infant-directed aggression. Behav Brain Res 2009; 199: 340-344.
52. He J, et al,. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol 2004; 189: 404-412. (Pubitemid 39221832)
53. Magnaghi V, et al,. Neuroactive steroids and peripheral myelin proteins. Brain Res Rev 2001; 37: 360-371. (Pubitemid 34020744)
54. West MJ, et al,. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 2004; 25: 1205-1212. (Pubitemid 39094023)
55. Leonelli E, et al,. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 2007; 144: 1293-1304. (Pubitemid 46123820)
56. Michael T,. Macfarlane, Urology; Ch. 19 Benign Prostatic Hyperplasia, 4th edn. Philadelphia, PA: Pub. Lippincott Williams & Wilkins, 2006: 115-122.
57. Lagiou P, et al,. Serum steroids in relation to benign prostatic hyperplasia. Oncology 1997; 54: 497-501. (Pubitemid 27470261)
58. Brodeur MR, Thiompson JF,. Geriatric urologic disorders. In:, Koda-Kimble MA, et al., eds. Applied Therapeutics: The Clinical Use of Drugs, 9th edn. Philadelphia, PA: Pub. Lippincott Williams & Wilkins, 2008: 101-115.
59. Macfarlane MT,. Urology; Ch. 22 Prostatic Cancer, 4th edn. Philadelphia, PA: Pub. Lippincott Williams & Wilkins, 2006: 145-155.
60. Cooke GM, et al,. The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha- reductase activity. J Steroid Biochem Mol Biol 1997; 60: 353-359. (Pubitemid 27278069)
61. Sadler T,. Urogenital system. In: Langman's Medical Embryology, 9th edn. Philadelphia, PA: Pub. Lippincott Williams & Wilkins, 2004: 235-262.
62. Losos JB, et al,. Biology. New York: McGraw-Hill, 2002: 1207-1209.
63. Hu L, et al,. 'Converse regulatory functions of estrogen receptor-alpha and -beta subtypes expressed in hypothalamic gonadotropin-releasing hormone neurons'. Mol Endocrinol 2008; 22: 2250-2259.
64. Soronen P, et al,. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 281-286. (Pubitemid 40128249)
65. Wilson JD,. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 2001; 13: 673-678. (Pubitemid 34240215)
66. Fujioka S, et al,. The Arabidopsis deetiolated2 mutant is blocked early in brassinosteroid biosynthesis. Plant Cell 1997; 9: 1951-1962. (Pubitemid 28174068)
67. Sondhi N, et al,. 'Isolation of 24-epibrassinolide from leaves of 'Aeglemarmelos' and evaluation of its antigenotoxicity potential employing Allium cepachromosomal aberration assay. Plant Growth Regul 2008; 54: 217-224.
68. Sharma P, Bhardwaj R,. Effects of 24-Epibrassinolide on growth and metal uptake in 'Brassica juncea' L. under copper metal stress. Acta Physiol Plant 2007; 29: 259-263. (Pubitemid 46800618)
69. Luo M, et al,. GhDET2, a steroid 5alpha-reductase, plays an important role in cotton fiber cell initiation and elongation. Plant J 2007; 51: 419-430. (Pubitemid 47106539)
70. Kontturi M, et al,. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone resistant metastatic prostatic cancer. Eur Urol 1988; 15: 43-47. (Pubitemid 19000801)
71. Lee JR,. Why would men need to take progesterone? Natural-progesterone- advisory-network.com (Internet), Australia. 2010 Available at: (accessed 20 August 2010).
72. Marisa C, et al,. New progesterone derivatives as inhibitors of 5 alpha-reductase enzyme and prostate cancer cell growth. J Enzyme Inhib Med Chem 2006; 21: 371-378.
73. Sauter ER, et al,. Prostate-specific antigen production in the female breast: association with progesterone. Cancer Epidemiol Biomarkers Prev 1998; 7: 315-320. (Pubitemid 28354143)
74. Yu H,. Clinical implications of prostate-specific antigen in men and women. J Gend Specif Med 2000; 3: 45-48. 53.
75. Yasuda N, et al,. Effects of steroid 5 alpha reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Jpn J Pharmacol 1997; 74: 243-252. (Pubitemid 27376038)
76. Cabeza M, et al,. New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth. J Enzyme Inhib Med Chem 2006; 21: 371-378. (Pubitemid 44355785)
77. Bratoeff E, et al,. Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors. J Enzyme Inhib Med Chem 2009; 24: 655-662.
78. Flores E, et al,. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem 2003; 3: 225-237.
79. Bratoeff E, et al,. Synthesis and biological activity of progesterone derivatives as 5alpha-reductase inhibitors, and their effect on hamster prostate weight. J Enzyme Inhib Med Chem 2010; 25: 306-311.
80. Bratoeff E, et al,. Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors. Curr Med Chem 2005; 12: 927-943. (Pubitemid 40443848)
81. Pérez-Ornelas V, et al,. New 5alpha-reductase inhibitors: in vitro and in vivo effects. Steroids 2005; 70: 217-224. (Pubitemid 40342616)
82. Cabeza M, et al,. Novel C-6 substituted and unsubstitutedpregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size. Steroids 2009; 74: 793-802.
83. Srinivasan G, et al,. Androgen, estrogen, and progesterone receptors in normal and aging prostates. Microsc Res Tech 1995; 30: 293-304.
84. Anderström C,. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer. Cancer Chemother Pharmacol 1994; 35 (Suppl.): S97-100. (Pubitemid 24357252)
85. Chau I, Cunningham D,. Cancers of genitourinary tract (prostrate). In:, Francesco C, et al., eds. Textbook of Medical Oncology, 3rd edn. Northway, UK: Oncology Informa Health Care, Thompson Publishing services, 2004: 215.
86. de Sousa FL, et al,. Progesterone and maternal aggressive behavior in rats. Behav Brain Res 2010; 212: 84-89.
87. Schneider JS, et al,. Progesterone receptors mediate male aggression toward infants. Proc Natl Acad Sci USA 2003; 100: 2951-2956. (Pubitemid 36297604)
88. Pinna G, et al,. Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochem Res 2008; 33: 1990-2007.
89. Northwestern University. Progesterone regulates male behavior toward infants. Science Daily (Internet). 2003. Available at: (accessed 30 June 2010).
90. Schneider JS, et al,. Progesterone receptors mediate male aggression toward infants. Proc Natl Acad Sci USA 2003; 100: 2951-2956. (Pubitemid 36297604)
91. Nephew BC, et al,. The progesterone receptor and parental behavior in juvenile rats. Dev Psychobiol 2008; 50: 535-541.
92. Wynne-Edwards KE, Timonin ME,. Paternal care in rodents: weakening support for hormonal regulation of the transition to behavioral fatherhood in rodent animal models of biparental care. Horm Behav 2007; 52: 114-121. (Pubitemid 46809867)
93. MunkJensen N, et al,. Reversal of postmenopausal vertebral bone loss by estrogen and progesteron: a double-blind placebo controlled study. BMJ 2008; 296: 1150-1152.
94. Prior J,. Reported in 'provera alone builds bone medical tribune. 4-5, July 22, 1987.
95. Lee JR,. Osteoporosis reversal: the role of progesterone. Int Clin Nutr Rev 1990; 10: 384-391.
96. Burry KA, et al,. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 1999; 180: 1504-1511. (Pubitemid 29293279)
97. Liu JH, Muse KN,. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 2005; 192: 1316-1323. discussion 1323-4.
98. Greenwald MW,. Oral hormone therapy with 17[beta]-estradiol and 17[beta]-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005; 12: 741-748. (Pubitemid 41669127)
99. Lloyd T, et al,. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertil Steril 2000; 74: 734-738.
100. Clark MK, et al,. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2006; 86: 1466-1474. (Pubitemid 44602060)
101. Petitti DB, et al,. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000; 95: 736-744. (Pubitemid 30210062)
102. Perrotti M, et al,. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril 2001; 76: 469-473.
103. Wanichsetakul P, et al,. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot- medroxyprogesterone acetate for contraception. Contraception 2002; 65: 407-410. (Pubitemid 34804542)
104. Hartard M, et al,. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone 2007; 40: 444-450. (Pubitemid 46075201)
105. Broulík PD, et al,. Progestagens androgenic action on the bone of male castrated mice. Prague Med Rep 2006; 107: 401-408.
106. Schoonen WG, et al,. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol 2000; 74: 213-222. (Pubitemid 32121657)
107. Levin ER, Hammes SR,. Estrogens and Progestin. In:, Brunton L, ed. Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th edn. New York, NY: McGraw Hill Publishers, 2011: 1181.
108. Christiansen C,. Prevention and treatment of osteoporosis: a review of current modalities. Bone 1992; (Suppl.) 1: 35-39.
109. Delmas PD, et al,. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000; 11: 177-187. (Pubitemid 30168805)
110. Broulík PD, et al,. Effect of exogenous estrogen on male rats bone. SbLek 1999; 100: 219-222.
111. Stevenson JC, et al,. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265-269. (Pubitemid 20229121)
112. Rubinacci A, et al,. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause 2003; 10: 241-249. (Pubitemid 36706310)
113. Wren BG, et al,. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003; 10: 13-18. (Pubitemid 36706317)
114. Christiansen C, et al,. Bone mass in postmenopausal women after withdrawal of oestrogen/getsten replacement therapy. Lancet 1981; 1: 459-461. (Pubitemid 11130971)
115. Christiansen C, et al,. Prevention of postmenopausal bone loss: controlled 2 year study in 315 normal females. Eur J Clin Invest 1980; 280: 822-826.
116. Christiansen C, Riis B,. 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836-841.
117. McClung M, et al,. Efficacy of Activelle to increase bone mineral density in postmenopausal women. Bone 1998; 23/5 (Suppl.): S465.
118. Roux C, et al,. Randomized, double-masked, 2-year comparison of tibolone with 17beta- estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int 2002; 13: 241-248. (Pubitemid 34408192)
119. Popp AW, et al,. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Maturitas 2006; 53: 191-200.
120. Arabi A, et al,. Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study. Human Reprod 2003; 18: 1747-1752. (Pubitemid 36958062)
121. Arrenbrecht S, et al,. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women. Maturitas 2004; 48: 197-207. (Pubitemid 38781145)
122. Ravn P, et al,. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999; 131: 935-942. (Pubitemid 30005033)
123. Tang OS, et al,. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception 1999; 59: 25-29. (Pubitemid 29174414)
124. Pongsatha S, et al,. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study. J Med Assoc Thai 2009; 92: 1263-1267.
125. Cromer BA, et al,. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004; 35: 434-441. (Pubitemid 39576013)
126. Clark MK, et al,. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82: 1580-1586. (Pubitemid 39611386)
127. Albertazzi P, et al,. Bone mineral density and depot medroxyprogesterone acetate. Contraception 2006; 73: 577-583. (Pubitemid 43786283)
128. Bahamondes L, et al,. dos Santos FernandesAM.Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception 2006; 74: 259-263. (Pubitemid 44175360)
129. Berenson AB, et al,. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004; 103: 899-906. (Pubitemid 40458990)
130. Cromer BA, et al,. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008; 90: 2060-2067.
131. Curtis KM, Martins SL,. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006; 73: 470-487.
132. Kaunitz AM, et al,. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008; 77: 67-76.
133. Shaarawy M, et al,. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 2006; 74: 297-302. (Pubitemid 44373881)
134. Viola AS, et al,. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. Contraception 2011; 84: 122-127.
135. Bahamondes L, et al,. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum Reprod 2006; 21: 466-470. (Pubitemid 43159924)
136. Bahamondes L, et al,. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod 2006; 21: 1316-1319.
137. Rickard DJ, et al,. Bone growth and turnover in progesterone receptor knockout mice. Endocrinology 2008; 149: 2383-2390. (Pubitemid 351574494)
138. Yao W, et al,. Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice. PLoS ONE 2010; 5: e11410.
139. Meher S, Duley L,. Progesterone for preventing pre-eclampsia and its complications. The Cochrane Library 2009, Issue 3). Available at: (accessed 20 August 2011).
140. Mizutani S, et al,. Positive effect of estradiol and progesterone in severe pre-eclampsia. Exp Clin Endocrinol 1988; 92: 161-170. (Pubitemid 19051592)
141. Buhimschi I, et al,. Pre-eclampsia-like conditions produced by nitric oxide inhibition: effects of L-arginine, d-arginine and steroid hormones. Hum Reprod 1995; 10: 2723-2730.
142. Dalton K,. Ante-natal progesterone and intelligence. Br J Psychiatry 1968; 114: 1377-1382.
143. Dalton K,. Controlled trials in the prophylactic value of progesterone in the treatment of pre-eclamptictoxaemia. J Obstet Gynaecol Br Commonw 1969; 3: 463-468.
144. Hauth JC, et al,. The effect of 17-alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-dury military population. Am J Obstet Gynecol 1983; 146: 187-190. (Pubitemid 13092766)
145. Zeisler H, et al,. Serum levels of progesterone in patients with preeclampsia. Wien Klin Wochenschr 2000; 112: 362-364. (Pubitemid 30256681)
146. Rosing U, Carlström K,. Serum levels of unconjugated and total oestrogens and dehydroepiandrosterone, progesterone and urinary oestriol excretion in pre-eclampsia. Gynecol Obstet Invest 1984; 18: 199-205. (Pubitemid 14008854)
147. Iou S, et al,. Evaluation of androgen and progesterone levels in women with preeclampsia. MJIAS 2005; 15: 19-22.
148. Tamimi R, et al,. Pregnancy hormones, pre-eclampsia,and implications for breast cancer risk in the offspring. Cancer Epidemiol Biomarkers Prev 2003; 12: 647-650. (Pubitemid 36899846)
149. Lynch A, Mychalkiw W,. Prenatal progesterone II. Its role in the treatment of pre-eclamptictoxaemia and its effect on the off-spring's intelligence: a reappraisal. Early Hum Dev 1978; 2: 323-339. (Pubitemid 9063945)
150. Thangaratinam S, et al,. Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25: 419-433.
151. Sammour MB, et al,. Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens. J Steroid Biochem Mol Biol 2005; 97: 439-440. (Pubitemid 41691884)
152. Chaudhri N, et al,. Sex differences in the contribution of nicotine and non-pharmacological stimuli to nicotine self-administration in rats. Psychopharmacology 2005; 180: 258-266. (Pubitemid 40909671)
153. Donny EC, et al,. Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding. Psychopharmacology 2000; 151: 392-440.
154. Rezvani AH, et al,. Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: persisting effects on locomotor activity, learning and nicotine self-administration. Neuroscience 2008; 154: 885-897.
155. DeBon M, et al,. Symptomatology across the menstrual cycle in smoking and nonsmoking women. Addict Behav 1995; 20: 335-343.
156. Mello NK, et al,. Cigarette smoking by women: interactions with alcohol use. Psychopharmacology 1987; 93: 8-15. (Pubitemid 17143719)
157. Snively TA, et al,. Smoking behavior, dysphoric states and the menstrual cycle: results from single smoking sessions and the natural environment. Psychoneuroendocrinology 2000; 25: 677-691. (Pubitemid 30628430)
158. Allen SS, et al,. Withdrawal and pre-menstrual symptomatologyduring the menstrual cycle in short-term smoking abstinence: effects of menstrual cycle on smokingabstinence. Nicotine Tob Res 1999; 1: 129-142.
159. Pomerleau CS, et al,. Effects of menstrual phase and smoking abstinence in smokers with and without a history of major depressive disorder. Addict Behav 2000; 25: 483-497. (Pubitemid 30326745)
160. Franklin TR, et al,. Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Womens Health 2008; 17: 287-292. (Pubitemid 351631249)
161. Lynch WJ,. Sex and ovarian hormones influence vulnerability and motivation for nicotine during adolescence in rats. Pharmacol Biochem Behav 2009; 94: 43-50.
162. Allen SS, et al,. Menstrual phase effects on smoking relapse. Addiction 2008; 103: 809-821. (Pubitemid 351537675)
163. Carpenter MJ, et al,. Menstrual cycle phase effects on nicotine withdrawal and cigarette craving: a review. Nicotine Tob Res 2006; 8: 627-638. (Pubitemid 44480412)
164. Evans SM, Foltin RW,. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacology 2006; 31: 659-674. (Pubitemid 43276982)
165. Smith SS,. Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience 1991; 42: 309-320.
166. Sofuoglu M, et al,. Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers. Hum Psychopharmacol 2009; 24: 559-564.
167. Bullock AE, et al,. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J Neurochem 1997; 68: 2412-2423. (Pubitemid 27218162)
168. Amory JK, et al,. Drug insight: recent advances in male hormonal contraception. Nat Clin Pract Endocrinol Metab 2006; 2: 32-41.
169. Anon. 'Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility'. Lancet 1990; 336: 955-959.
170. Zhang FP, et al,. The low gonadotropin-independent constitutiveproductionoftesticular testosteroneis sufficient to maintain spermatogenesis. Proc Natl Acad Sci USA 2003; 100: 13692-13697.
171. Gonzalo IT, et al,. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 2002; 87: 3562-3572. (Pubitemid 34879497)
172. Hair WM, et al,. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab 2001; 86: 5201-5209. (Pubitemid 33070236)
173. Anderson RA, et al,. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5α-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 1996; 81: 902-908.
174. McLachlan RI, et al,. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab 2002; 87: 546-556. (Pubitemid 34158217)
175. Amory JK,. Male hormonal contraceptives: current status and future prospects. Treat Endocrinol 2005; 4: 333-341. (Pubitemid 41751169)
176. Amory JK,. Testosterone/progestin regimens: a realistic option for male contraception? Curr Opin Investig Drugs 2004; 5: 1025-1030.
177. Knuth UA, Nieschlag E,. Endocrine approaches to male fertility control. Baillieres Clin Endocrinol Metab 1987; 1: 113-131. (Pubitemid 17150576)
178. Stein DG,. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev 2008; 57: 386-397. (Pubitemid 351381771)
179. Baulieu EE, et al,. Neurosteroids: beginning of the story. Int Rev Neurobiol 2001; 46: 1-32. (Pubitemid 33798716)
180. Herson PS, et al,. Sex, sex steroids and brain injury. Semin Reprod Med 2009; 27: 229-239.
181. Langlois JA, et al,. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths. Atlanta, GA: US Department of Health and Human Services, CDC, 2004.
182. Roberts I, et al,. Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review. Neurol Neurosurg Psychiatry 1998; 65: 729-733. (Pubitemid 28486654)
183. Muzelaar JP, et al,. Improving the outcome of severe head injury with oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase trial. J Neurosury 1993; 78: 375-382.
184. Roof RL, et al,. Gender influences outcome of brain injury: progesterone play a protective role. Brain Res 1993; 607: 333-336. (Pubitemid 23104985)
185. Stein DG,. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? Trends Neurosci 2001; 24: 386-391. (Pubitemid 32938541)
186. Wright DW, et al,. 'ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49: 391-402. 402.
187. Djebaili M, et al,. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005; 22: 106-118.
188. Roof RL, Hall ED,. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma 2000; 17: 367-388. (Pubitemid 30327300)
189. Roof RL, et al,. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol. 1994, 129: 64-69. (Pubitemid 24344157)
190. Roof RL, et al,. Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol Chem Neuropathol 1997; 31: 1-11. (Pubitemid 27328632)
191. Roof RL, et al,. Progesterone treatment attenuates brain edema following contusion injury in male and female rats. Restor Neurol Neurosci 1992; 4: 425-427. (Pubitemid 23001029)
192. Ransohoff RM, Tani M,. Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation? Trends Neurosci 1998; 21: 154-159. (Pubitemid 28157184)
193. Asbury ET, et al,. Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat. Behav Brain Res 1998; 97: 99-106. (Pubitemid 28558853)
194. Shear DA, et al,. Progesterone protects gainst necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002; 178: 59-67. (Pubitemid 35425609)
195. Chen J, et al,. Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rat. Neurol Sci 1999; 171: 24-30. (Pubitemid 29525574)
196. Thomas AJ, et al,. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 1999; 24: 2134-2138. (Pubitemid 29489429)
197. Kumon Y, et al,. Neuroprotective effects of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg 2000; 92: 848-852. (Pubitemid 30243934)
198. Pettus EH, et al,. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res 2005; 1049: 112-119. (Pubitemid 40814581)
199. Xiao G, et al,. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008; 12: R61.
200. Wright DW, et al,. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma 2001; 18: 901-909. (Pubitemid 32852891)
201. Janice H, et al,. Protection from traumatic brain injury in hormonally active women vs men of a similar age: a retrospective international study. Arch Surg 2011; 146: 436-442.
202. Sidaros A, et al,. Long-term global and regional brain volume changes following severe traumatic brain injury: a longitudinal study with clinical correlates. Neuroimage 2009; 44: 1-8.
203. Atif F, et al,. Progesterone with Vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol Med 2009; 15: 328-336.
204. Margulies S, Hicks R, the Combination Therapies for Traumatic Brain Injury Workshop Leaders. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma 2009; 26: 925-939.
205. Stein DG,. Sex differences in brain damage and recovery of function: experimental and clinical findings. Prog Brain Res 2007; 161: 339-351. (Pubitemid 47017414)
206. Clinical Trial Registry India.org (CTRI). National Institute of Health, USA: progesterone for the treatment of traumatic brain injury (ProTECT III) (Internet). 2011 (updated 2011 July 14; cited on 2011 Dec 9). Available at: (accessed 14 December 2011).
207. Vandromme M, et al,. Progesterone in traumatic brain injury: time to move on to phase III trials. Crit Care 2008; 12: 153.
208. Stein DG,. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev 2008; 57: 386-397. (Pubitemid 351381771)
209. Cekic M, et al,. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol Aging 2011; 32: 864-874.
210. Guennoun R, et al,. The membrane-associated progesterone-binding protein 25-Dx: expression, cellular localization and up-regulation after brain and spinal cord injuries. Brain Res Rev 2008; 57: 493-505. (Pubitemid 351381763)
211. Brinton RD, et al,. Progesterone receptors: form and function in brain. Neuroendocrinol 2008; 29: 313-339.
212. Thomas P,. Characteristics of membrane progestin receptor alpha (mPRα) and progesterone membrane receptor component one (PGMRC1) and their roles in mediating rapid progestin actions. Neuroendocrinol 2008; 29: 292-312.
213. Hwang JY, et al,. Progesterone potentiates calcium release through IP3 receptors by an Akt-mediated mechanism in hippocampal neurons. Cell Calcium 2009; 45: 233-242.
214. Singh M,. Ovarian hormoneselicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. Endocrine 2001; 14: 407-415. (Pubitemid 32547825)
215. Roux PP, Blenis J,. ERK and p38 MAPKactivated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-344. (Pubitemid 38756868)
216. Kaur P, et al,. Progesterone increases BDNF expression and protects against glutamate toxicity in A MAPK- And Pi3-K-dependent manner in cerebral cortical explants. J Neurosci Res 2007; 85: 2441-2449.
217. Meyer M, et al,. Progesterone effects on neuronal brain-derived neurotrophic factor and glial cells during progression of Wobbler mouse neurodegeneration. Neuroscience 2011; 201: 267-279.
218. Coughlan T, et al,. Progesterone, BDNF and neuroprotection in the injured CNS. Int J Neurosci 2009; 119: 1718-1740.
219. Wise PM, et al,. neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 2001; 142: 969-973. (Pubitemid 32202802)
220. Gibson CL, et al,. 'Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008; 131: 318-328. (Pubitemid 351197603)
221. Roof RL, et al,. Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp Neurol 1996; 138: 246-251. (Pubitemid 26132712)
222. Junpeng M, et al,. Progesterone for acute traumatic brain injury. Cochrane Database Syst Rev 2011; (1): CD008409.
223. Stein DG, et al,. Does progesterone have neuroprotective properties? Ann Emerg Med 2008; 51: 164-172.
224. Roof RL, Fritts ME,. Progesterone metabolites may mediate its neuroprotective effects after traumatic brain injury. Neurotrauma 1997; 14: 760.
225. Cai W, et al,. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 2008; 55: 127-138.
226. Baulieu EE, et al,. Neurosteroids: beginning of the story. Int Rev Neurobiol 2001; 46: 1-32. (Pubitemid 33798716)
227. Schumacher M, et al,. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007; 116: 77-106. (Pubitemid 47398920)
228. Komesaroff PA, et al,. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 2001; 4: 144-150. (Pubitemid 32578829)
229. A Phase 3 Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries Sponsored by BHR Pharma, LLC. SyNAPSe. BHR Pharma, LLC, A Besin Healthcare Company (Internet). 2009. Available at: (accessed 26 November 2012).
230. Auger CJ, ForbesLorman RM,. Progestin receptor mediated reduction of anxiety-like behaviour in male rats. PLoS ONE 2008; 3: e3606.
231. Chen Z, et al,. Effects of progesterone and testosterone on ICH-induced brain injury in rats. Acta Neurochir Suppl 2011; 111: 289-293.
232. Wang J, et al,. Neuroprotective effects of progesterone following stroke in aged rats. Behav Brain Res 2010; 209: 119-122.
233. Gibson CL, et al,. Progesterone suppresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia. Exp Neurol 2005; 193: 522-530. (Pubitemid 40616199)
234. Zhang Z, et al,. Treatment with progesterone after focal cerebral ischemia suppresses proliferation of progenitor cells but enhances survival of newborn neurons in adult male mice. Neuropharmacology 2010; 58: 930-939.
235. Murphy SJ, et al,. Progesterone exacerbates striatal stroke injury in progesterone-deficient female animals. Stroke 2000; 31: 1173-1178. (Pubitemid 30253542)
236. Coomber B, Gibson CL,. Sustained levels of progesterone prior to the onset of cerebral ischemia are not beneficial to female mice. Brain Res 2010; 18: 124-132.
237. Jiang C, et al,. Microglia and cyclooxygenase-2: possible therapeutic targets of progesterone for stroke. IntImmunopharmacol 2011; 11: 1925-1931.
238. Ishrat T, et al,. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol 2010; 226: 183-190.
239. Chen S, et al,. Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease. PLoS ONE 2011; 6: e24293.
240. Brinton RD, Wang JM,. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept Neurogenic agent. Curr Alzheimer Res 2006; 3: 185-190. (Pubitemid 43988130)
241. Marx CE, et al,. The neurosteroidallopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 2006; 60: 1287-1294. (Pubitemid 44838538)
242. Schumacher M, et al,. 'Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination'. Growth Horm IGF Res 2004; 14 (Suppl. A): S18-S33. (Pubitemid 38701823)
243. Chen B, et al,. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase->AKT->GSK-3beta->cyclin D1->pRB pathway to block uterine epithelial cell proliferation. Mol Endocrinol 2005; 19: 1978-1990. (Pubitemid 41124196)
244. Chuang DM, et al,. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011; 4: 15.
245. Rowe MK, et al,. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007; 31: 920-931. (Pubitemid 47285347)
246. Coirini H, et al,. 3 Beta-hydroxysteroid dehydrogenase expression in rat spinal cord. Neuroscience 2002; 113: 883-891. (Pubitemid 35245257)
247. Morrow AL,. Recent developments in the the significance and therapeutic relevance of neuroactive steroids-Introduction to the special issue. Pharmacol Ther 2007; 116: 1-6. (Pubitemid 47393686)
248. Mellon SH,. Neurosteroid regulation of CNS development. Pharmacol Ther 2007; 116: 107-124.
249. Compagnone NA, Mellon SH,. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 2000; 21: 1-58.
250. Smith SS, et al,. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology (Berl) 2006; 186: 323-333. (Pubitemid 43800834)
251. Spence KT, et al,. The neurosteroidspregnenolone and pregnenolone-sulfate but not progesterone, block Ca2+ currents in acutely isolated hippocampal CA1 neurons. Life Sci 1991; 49: PL235-PL239.
252. Spigelman I, et al,. Behavior and physiology of mice lacking the GABAA-receptor delta subunit. Epilepsia 2002; 43 (Suppl. 5): 3-8. (Pubitemid 34864198)
253. Colin J, et al,. Neuroprotective actions of brain aromatase front. Neuroendocrinol 2009; 30: 106-118.
254. Stell BM, Mody I,. Receptors with different affinities mediate phasic and tonic GABA(A) conductances in hippocampal neurons. J Neurosci 2002; 22: RC223.
255. Stoffel-Wagner B,. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci 2003; 1007: 64-78. (Pubitemid 38253655)
256. Suzuki M, et al,. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci USA 2004; 101: 3202-3207. (Pubitemid 38327758)
257. Micevych P, et al,. Neuroprogesterone: key to estrogen positive feedback? Brain Res Rev 2008; 57: 470-480. (Pubitemid 351391958)
258. Wang JM, et al,. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr Alzheimer Res 2007; 4: 510-517.
259. Wang JM, et al,. Regenerative potential of allopregnanolone. Brain Res Rev 2008; 57: 398-409. (Pubitemid 351381778)
260. Adams JH, Duchen LW,. Greenfield's Neuropathology, 5th edn. New York, NY: Oxford University Press, 1992: 1160-1166.
261. Zhang HM, et al,. Acute nerve injury induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn of intact rat. Sheng Li XueBao 2004; 56: 591-596.
262. Roglio I, et al,. Neuroactive steroids and peripheral neuropathy. Brain Res Rev 2008; 57: 460-469. (Pubitemid 351381761)
263. Cermenati G, et al,. Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy. J Neurosci 2010; 30: 11896-11901.
264. Sheikh N, et al,. Decreased endogenous progesterone and ratio of progesterone to estrogen in stroke ischemia. Afr J Biotechnol 2010; 9: 732-734.
265. Kovacic U, et al,. Sex-related difference in collateral sprouting of nociceptive axons after peripheral nerve injury in the rat. Exp Neurol 2003; 184: 479-488. (Pubitemid 37444055)
266. Milani P, et al,. Progesterone-new therapy in mild carpal tunnel syndrome? Study design of a randomized clinical trial for local therapy. J Brachial Plex Peripher Nerve Inj 2010; 5: 11.
267. Werner RA, Andary M,. Carpal tunnel syndrome: pathophysiology and clinical neurophysiology. Clin Neurophysiol 2002; 113: 1373-1381.
268. Marshall S, et al,. Local corticosteroid injection for carpal tunnel syndrome. Cochrane Database Syst Rev 2002; (4): CD001554.
269. Marshall S, et al,. Local corticosteroid injection for carpal tunnel syndrome. Cochrane Database Syst Rev 2000; (4): CD001554.
270. Marshall S, et al,. Local corticosteroid injection for carpal tunnel syndrome. Cochrane Database Syst Rev 2007; (2): CD001554.
271. Coronel MF, et al,. Progesterone prevents nerve injury-induced allodynia and spinal NMDA receptor upregulation in rats. Pain Med 2011; 12: 1249-1261.
272. Roglio I, et al,. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience 2008; 155: 673-685.
273. Roglio I, et al,. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience 2008; 155: 673-685.
274. Meyer L, et al,. Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci 2010; 67: 3017-3034.
275. Melcangi RC, Garcia-Segura LM,. Therapeutic approaches to peripheral neuropathy based on neuroactive steroids. Expert Rev Neurother 2006; 6: 1121-1125. (Pubitemid 44231970)
276. Melcangi RC, Mensah-Nyagan AG,. Neurosteroids: measurement and pathophysiologic relevance. Neurochem Int 2008; 52: 503-505. (Pubitemid 351146674)
277. Cummins CL, et al,. Liver X receptors regulate adrenal cholesterol balance. J Clin Invest 2006; 116: 1902-1912. (Pubitemid 44033314)
278. Giatti S, et al,. Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009; 164: 520-529.